Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6623546rdf:typepubmed:Citationlld:pubmed
pubmed-article:6623546lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0034493lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0026259lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:6623546lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:6623546pubmed:issue1-2lld:pubmed
pubmed-article:6623546pubmed:dateCreated1983-11-23lld:pubmed
pubmed-article:6623546pubmed:abstractTextThe acute effects of a single i.v. bolus injection of mitoxantrone (MX), a cytostatic drug, on mean arterial pressure (MAP), left ventricular pressure (LVP), dp/dtmax and ECG, were investigated at different doses (1,2,3,5 and 10 mg/kg) in conscious rabbits. Low values of MAP, LVP and dp/dtmax and increased heart rate were observed at 2 h after injection at all dose levels exceeding 1 mg/kg. Plasma kinetics and urinary elimination of MX were determined by high-pressure liquid chromatography (HPLC) and appraised at two dose levels (1.5 mg/kg and 3 mg/kg). MX plasma decay curve at both doses could be fitted to a curve with three exponential components, with an average elimination (3rd component) half-life of about 3.5 h (1.5 mg/kg) and about 5 h (3 mg/kg), respectively. Renal failure was observed in 3 mg/kg-dosed rabbits (elevation of BUN and plasma creatinine, anuria), and resulted in a considerable delay in the MX plasma decay and in a depressed urinary elimination of MX. All but one rabbit died within 24 h. The 1.5 mg/kg-dosed rabbits survived till 24 h, without signs of renal failure, with a 24 h urinary MX recovery of 20%.lld:pubmed
pubmed-article:6623546pubmed:languageenglld:pubmed
pubmed-article:6623546pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6623546pubmed:citationSubsetIMlld:pubmed
pubmed-article:6623546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6623546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6623546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6623546pubmed:statusMEDLINElld:pubmed
pubmed-article:6623546pubmed:monthAuglld:pubmed
pubmed-article:6623546pubmed:issn0378-4274lld:pubmed
pubmed-article:6623546pubmed:authorpubmed-author:DumontEElld:pubmed
pubmed-article:6623546pubmed:authorpubmed-author:HarvengtCClld:pubmed
pubmed-article:6623546pubmed:authorpubmed-author:HulhovenRRlld:pubmed
pubmed-article:6623546pubmed:issnTypePrintlld:pubmed
pubmed-article:6623546pubmed:volume18lld:pubmed
pubmed-article:6623546pubmed:ownerNLMlld:pubmed
pubmed-article:6623546pubmed:authorsCompleteYlld:pubmed
pubmed-article:6623546pubmed:pagination19-26lld:pubmed
pubmed-article:6623546pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:meshHeadingpubmed-meshheading:6623546-...lld:pubmed
pubmed-article:6623546pubmed:year1983lld:pubmed
pubmed-article:6623546pubmed:articleTitleAcute cardiovascular and renal changes induced by mitoxantrone in rabbits. A pharmacokinetic approach.lld:pubmed
pubmed-article:6623546pubmed:publicationTypeJournal Articlelld:pubmed